Molecular and clinical progress in follicular lymphoma lacking the t(14;18) translocation (Review)
- Authors:
- Zunmin Zhu
- Tao Li
- Xuran Zhang
- Zhengqiang Zhang
- Dandan Zhu
- Pei Lin
- Shichun Tu
- Weihong Ren
-
Affiliations: Institute of Hematology, Henan Renmin Hospital, Zhengzhou, Henan 475000, P.R. China, Laboratory of Hematology, The First Affiliated Hospital of Zhenzhou University, Zhengzhou, Henan 475000, P.R. China, Department of Laboratory Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China, Immunology Laboratory of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan 450008, P.R. China, Zhengzhou Shenyou Biotechnology, Zhengzhou, Henan 450000, P.R. China, Department of Hematopathology, MD Anderson Cancer Center, Houston, TX 77030, USA, Scintillon Institute for Biomedical and Bioenergy Research, San Diego, CA 92121, USA - Published online on: November 21, 2019 https://doi.org/10.3892/ijo.2019.4917
- Pages: 7-17
This article is mentioned in:
Abstract
 |
 |
|
Abd El-Ghaffar HA, Shamaa S, Attwan N, et al: Stratification of Patients with Follicular Lymphoma. IntechOpen; Rijeka: 2012, https://www.intechopen.com/books/hematology-science-and-practice/stratification-of-patients-with-follicular-lymphoma. Accessed March 2, 2012. | |
|
Kridel R, Sehn LH and Gascoyne RD: Pathogenesis of follicular lymphoma. J Clin Invest. 122:3424–3431. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bisikirska B, Bansal M, Shen Y, Teruya-Feldstein J, Chaganti R and Califano A: Elucidation and pharmacological targeting of novel molecular drivers of follicular lymphoma progression. Cancer Res. 76:664–674. 2016. View Article : Google Scholar : | |
|
Katzenberger T, Kalla J, Leich E, Stöcklein H, Hartmann E, Barnickel S, Wessendorf S, Ott MM, Müller-Hermelink HK, Rosenwald A and Ott G: A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p-36. Blood. 113:1053–1061. 2009. View Article : Google Scholar | |
|
Casulo C, Burack WR and Friedberg JW: Transformed follicular non-Hodgkin lymphoma. Blood. 125:40–47. 2015. View Article : Google Scholar | |
|
Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D and Goodlad J: C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator? Leuk Lymphoma. 49:470–476. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bakhski A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL and Korsmeyer SJ: Cloning the chromosomal break-point of t(14;18) human lymphomas: Clustering around Jh on chromosome 14 and near a transcriptional unit on 18. Cell. 41:899–906. 1985. View Article : Google Scholar | |
|
Tsujimoto Y, Gorham J, Cossman J, Jaffe E and Croce CM: The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 229:1390–1393. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Cleary ML and Sklar J: Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA. 82:7439–7443. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Tsujimoto Y, Finger LR, Yunis J, Nowell PC and Croce CM: Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 226:1097–1099. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Graninger WB, Seto M, Boutain B, Goldman P and Korsmeyer SJ: Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest. 80:1512–1515. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Godon A, Moreau A, Talmant P, Baranger-Papot L, Geneviéve F, Milpied N, Zandecki M and Avet-Loiseau H: Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients Leukemia. 17:255–259. 2003. | |
|
Husson H, Carideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P and Freedman AS: Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 99:282–289. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Masir N, Campbell LJ, Goff LK, Jones M, Marafioti T, Cordell J, Clear AJ, Lister TA, Mason DY and Lee AM: BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol. 144:716–725. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Staudt LM: A closer look at follicular lymphoma. N Engl J Med. 356:741–742. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, Jouve N, Palli D, Pala V, Tumino R, et al: t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol. 32:1347–1355. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Graham C and LeBrun DP: Tumor suppressors in follicular lymphoma. Leuk Lymphoma. 56:1981–1988. 2015. View Article : Google Scholar | |
|
Gu K, Fu K, Jain S, Liu Z, Iqbal J, Li M, Sanger WG, Weisenburger DD, Greiner TC, Aoun P, et al: t(14;18)-negative follicular lymphomas are associated with a high frequency of BCL6 rearrangement at the alternative breakpoint region. Mod Pathol. 22:1251–1257. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Küppers R and Dalla-Favera R: Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 20:5580–5594. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Horsman DE, Okamoto I, Ludkovski O, Le N, Harder L, Gesk S, Siebert R, Chhanabhai M, Sehn L, Connors JM and Gascoyne RD: Follicular lymphoma lacking the t(14;18)(q32;q21): Identification of two disease subtypes. Br J Haematol. 120:424–433. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Vitolo U, Ferreri AJ and Montoto S: Follicular lymphomas. Crit Rev Oncol Hematol. 66:248–261. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD and Jaffe ES: The 2016 revision of theWorld Health Organization classification of lymphoid neoplasms. Blood. 127:2375–2390. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Samsi S, Lozanski G, Shana'ah A, Krishanmurthy AK and Gurcan MN: Detection of follicles from IHC-stained slides of follicular lymphoma using iterative watershed. IEEE Trans Biomed Eng. 57:2609–2612. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Paik PK, Johnson ML, D'Angelo SP, Sima CS, Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG and Riely GJ: Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 118:5840–5847. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Katzenberger T, Ott G, Klein T, Kalla J, Müller-Hermelink HK and Ott MM: Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol. 165:481–490. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Ott G, Katzenberger T, Lohr A, Kindelberger S, Rüdiger T, Wilhelm M, Kalla J, Rosenwald A, Müller JG, Ott MM and Müller-Hermelink HK: Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood. 99:3806–3812. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, Kalla J, Romero M, Siebert R, Rosenwald A and Ott G: Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 96:1327–1334. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Salaverria I and Siebert R: Follicular lymphoma grade 3B. Best Pract Res Clin Haematol. 24:111–119. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bosga-Bouwer AG, van Imhoff GW, Boonstra R, van der Veen A, Haralambieva E, van den Berg A, Jong B, Krause V, Palmer MC, Coupland R, et al: Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood. 101:1149–1154. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM, Sehn LH, Horsman DE, Gascoyne RD and Steidl C: Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Haematologica. 95:96–101. 2010. View Article : Google Scholar : | |
|
Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K and Kluin P: Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer. 27:85–94. 2000. View Article : Google Scholar | |
|
Weinberg OK, Ai WZ, Mariappan MR, Shum C, Levy R and Arber DA: 'Minor' BCL2 breakpoints in follicular lymphoma: Frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn. 9:530–537. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, et al: Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 114:826–834. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Leich E, Zamo A, Horn H, Haralambieva E, Puppe B, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al: MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. Blood. 118:5550–5558. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schraders M, de Jong D, Kluin P, Groenen P and van Krieken H: Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol. 205:329–335. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Skinnider BF, Horsman DE, Dupuis B and Gascoyne RD: Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol. 30:803–808. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Karube K, Kawano R, Suzumiya J, Takeshita M, Kikuchi M, Huang GS, Li Q and Ohshima K: Bcl2-negative follicular lymphomas frequently have Bcl6 translocation and/or Bcl6 or p53 expression. Pathol Int. 57:148–152. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jardin F, Gaulard P, Buchonnet G, Contentin N, Lepretre S, Lenain P, Stamatoullas A, Picquenot JM, Duval C, Parmentier F, et al: Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: A lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia. 16:2309–2317. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gollub W, Stassek B, Huckhagel T, Bernd HW, Krokowski M, Merz H, Feller AC and Thorns C: BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. Anticancer Res. 29:4649–4655. 2009.PubMed/NCBI | |
|
Pan Y, Meng B, Sun B, Guan B, Liang Y, Wang H, Hao X and Fu K: Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: Morphologic, immunohistochemical, and FISH analyses. Diagn Mol Pathol. 21:234–240. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Takeshita M, et al: CD10-MUM1 + follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 109:3076–3079. 2007. View Article : Google Scholar | |
|
Gagyi E, Balogh Z, Bödör C, Timár B, Reiniger L, Deák L, Csomor J, Csernus B, Szepesi A and Matolcsy A: Somatic hyper-mutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression. Haematologica. 93:1822–1828. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, Raffeld M, Hewitt SM and Jaffe ES: Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 37:333–343. 2013. View Article : Google Scholar : | |
|
Martin-Guerrero I, Salaverria I, Burkhardt B, Szczepanowski M, Baudis M, Bens S, de Leval L, Garcia-Orad A, Horn H, Lisfeld J, et al: Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas. Haematologica. 98:1237–1241. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jaffe ES: The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematol Am Soc Hematol Educ Program. 523–531. 2009. View Article : Google Scholar | |
|
Louissaint A Jr, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, Iafrate AJ, Lara DO, Pinkus GS, Salaverria I, et al: Pediatric-type nodal follicular lymphoma: An indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 120:2395–2404. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Araf S, Okosun J, Koniali L, Fitzgibbon J and Heward J: Epigenetic dysregulation in follicular lymphoma. Epigenomics. 8:77–84. 2016. View Article : Google Scholar : | |
|
Braggio E, Egan JB, Fonseca R and Stewart AK: Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J. 3:e1272013. View Article : Google Scholar : PubMed/NCBI | |
|
Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben JG and Davies JK: TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood. 128:72–81. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res. 31:1860–1861. 1971.PubMed/NCBI | |
|
Armitage JO and Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histo-logic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol. 16:2780–2795. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Horning SJ and Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 311:1471–1475. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Takata K, Miyata-Takata T, Sato Y and Yoshino T: Pathology of follicular lymphoma. J Clin Exp Hematop. 54:3–9. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nathwani BN: A promising new biologic prognostic model in diffuse large B-cell lymphoma. Blood. 120:2161–2162. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pezella F, Jones M, Ralfkiaer E, Ersbøll J, Gatter KC and Mason DY: Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer. 65:87–89. 1992. View Article : Google Scholar | |
|
Tomita N, Takasaki H, Miyashita K, Fujisawa S, Ogusa E, Matsuura S, Kishimoto K, Numata A, Fujita A, Ohshima R, et al: R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma. Br J Haematol. 161:383–388. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Siddhartha G and Vijay P: R-CHOP versus R-CVP in the treatment of follicular lymphoma: A meta-analysis and critical appraisal of current literature. J Hematol Oncol. 2:142009. View Article : Google Scholar : PubMed/NCBI | |
|
Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, et al: A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine-tositumomab. Clin Cancer Res. 19:6624–6632. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kahl BS and Yang DT: Follicular lymphoma: Evolving therapeutic strategies. Blood. 127:2055–2063. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:2188–2195. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 16:2825–2833. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Cang S, Iragavarapu C, Savooji J, Song Y and Liu D: ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 8:1292015. View Article : Google Scholar : PubMed/NCBI | |
|
Jazirehi AR and Bonavida B: Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene. 24:2121–2143. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Alas S, Emmanouilides C and Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 7:709–723. 2001.PubMed/NCBI | |
|
Leich E, Hoster E, Wartenberg M, Unterhalt M, Siebert R, Koch K, Klapper W, Engelhard M, Puppe B, Horn H, et al: Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia. 30:854–860. 2016. View Article : Google Scholar | |
|
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe R, Tomita N, Matsumoto C, Hattori Y, Matsuura S, Takasaki H, Hashimoto C, Fujita H, Fujisawa S and Ishigatsubo Y: The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era. J Clin Exp Hematop. 53:107–114. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Goodlad JR, Batstone PJ, Hamilton DA, Kernohan NM, Levison DA and White JM: BCL2 gene abnormalities define distinct clinical subsets of follicular lymphoma. Histopathology. 49:229–241. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wong YP, Faridah AR, Ahmad Toha S and Noraidah M: A case of t(14;18)-negative follicular lymphoma with unusual immunopheno-type: A diagnostic dilemma. Med Health. 6(1 Suppl): S2072011. | |
|
Nybakken GE, Bala R, Gratzinger D, Jones CD, Zehnder JL, Bangs CD, Cherry A, Warnke RA and Natkunam Y: Isolated follicles enriched for centroblasts and lacking t(14;18)/BCL2 in lymphoid tissue: Diagnostic and clinical implications. PLoS One. 11:e01517352016. View Article : Google Scholar : PubMed/NCBI | |
|
Kamatani T, Mishima K, Kutsuna T, Yoshihama Y, Kondo S and Shintani S: A case of surgical treatment for primary BCL2-'negative' follicular lymphoma without t(14;18) in early stage of the submandibular lymph node. J Oral Maxillofac Surg Med Pathol. 26:599–602. 2014. View Article : Google Scholar | |
|
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, et al: Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest. 126:3351–3362. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ahearn IM, Haigis K, Bar-Sagi D and Philips MR: Regulating the regulator: Post-translational modification of RAS. Nat Rev Mol Cell Biol. 13:39–51. 2012. View Article : Google Scholar | |
|
Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J, Smith LM, Zhang W, Kucuk C, Rinaldi A, et al: Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 123:1681–1690. 2014. View Article : Google Scholar : | |
|
Li H, Kaminski MS, Li Y, Yildiz M, Ouillette P, Jones S, Fox H, Jacobi K, Saiya-Cork K, Bixby D, et al: Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood. 123:1487–1498. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM, Offit K, Chaganti RS and Dalla-Favera R: Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci USA. 92:12520–12524. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Alhejaily A, Day AG, Feilotter HE, Baetz T and Lebrun DP: Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. Clin Cancer Res. 20:1676–1686. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung KJ, Johnson NA, Affleck JG, Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, et al: Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 70:9166–9174. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fitzgibbon J, Iqbal S, Davies A, O'Shea D, Carlotti E, Chaplin T, Matthews J, Raghavan M, Norton A, Lister TA and Young BD: Genome-wide detection of recurring sites of uniparental disomy in follicular and transformed follicular lymphoma. Leukemia. 21:1514–1520. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Oricchio E, Ciriello G, Jiang M, Boice MH, Schatz JH, Heguy A, Viale A, de Stanchina E, Teruya-Feldstein J, Bouska A, et al: Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. J Exp Med. 211:1379–1391. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, Ouillette P, Trifonov V, Rossi D, Tabbò F, et al: Genetics of follicular lymphoma transformation. Cell Rep. 6:130–140. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ross CW, Ouillette PD, Saddler CM, Shedden KA and Malek SN: Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res. 13:4777–4785. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schwaenen C, Viardot A, Berger H, Barth TF, Bentink S, Döhner H, Enz M, Feller AC, Hansmann ML, Hummel M, et al: Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer. 48:39–54. 2009. View Article : Google Scholar | |
|
Ogura M, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, et al: A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 165:768–776. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D, Bozek M, Iqbal S, et al: Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet. 46:176–181. 2014. View Article : Google Scholar : | |
|
Krajnovic M, Radojkovic M, Davidovic R, Dimitrijevic B and Krtolica K: Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. Med Oncol. 30:4412013. View Article : Google Scholar : PubMed/NCBI | |
|
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 476:298–303. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 42:181–185. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K and Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma: Association with extranodal disease and autoimmunity. Blood. 92:3018–3024. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Q, Wang G, Wang H, Hu Q and Ying Z: Folliculin, a tumor suppressor associated with Birt-Hogg-Dube (BHD) syndrome, is a novel modifier of TDP-43 cytoplasmic translocation and aggregation. Hum Mol Genet. 25:83–96. 2016. View Article : Google Scholar | |
|
Limpens J, Stad R, Vos C, de Vlaam C, de Jong D, van Ommen GJ, Schuuring E and Kluin PM: Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 85:2528–2536. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ and Stevenson FK: Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 99:2562–2568. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Chim CS, Wong KY, Loong F and Srivastava G: SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: Implications for epigenetic activation of the Jak/STAT pathway. Leukemia. 18:356–358. 2004. View Article : Google Scholar | |
|
Koyama M, Oka T, Ouchida M, Nakatani Y, Nishiuchi R, Yoshino T, Hayashi K, Akagi T and Seino Y: Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 83:1849–1858. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T, Yoshino T, Hayashi K, Ohara N, Nakanishi T, Yamaai Y, Hiraki A, Sogawa CA, Kondo E, Teramoto N, et al: Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: Combination analysis with cDNA expression array and tissue microarray. Am J Pathol. 159:1495–1505. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y and Seto M: TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 114:2467–2475. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, et al: Frequent inactivation of A20 in B-cell lymphomas. Nature. 459:712–716. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mottok A, Rennè C, Seifert M, Oppermann E, Bechstein W, Hansmann ML, Küppers R and Bräuninger A: Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood. 114:4503–4506. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung KJ, Delaney A, Ben-Neriah S, Schein J, Lee T, Shah SP, Cheung D, Johnson NA, Mungall AJ, Telenius A, et al: High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 49:669–681. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Launay E, Pangault C, Bertrand P, Jardin F, Lamy T, Tilly H, Tarte K, Bastard C and Fest T: High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia. 26:559–562. 2012. View Article : Google Scholar | |
|
O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, et al: The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 112:3126–3129. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES and Raffeld M: p53 mutation is associated with progression in follicular lymphoma. Blood. 82:1994–2004. 1993. View Article : Google Scholar : PubMed/NCBI |
